About Us

Gelomics is revolutionizing drug development by enabling the growth of human tissue models in vitro, providing an ethical, cost-effective, and predictive alternative to animal testing.

Leadership

The Gelomics leadership team is composed of experienced professionals dedicated to advancing the company’s vision of transforming drug discovery through innovative 3D cell culture solutions.

Christoph Meinert, PhD

Co-founder and Chief Executive Officer

Peter Levett, PhD

Co-founder and Chief Operating Officer

Hayley Zhang

Marketing Manager

Pawel Mieszczanek, PhD

Lead Engineer

Farhad Soheil, PhD

R&D Scientist

Scientific Advisory Board

These distinguished leaders in their fields bring a wealth of knowledge and expertise to Gelomics, helping to drive our mission of revolutionizing drug development with cutting-edge 3D cell culture technology.

Professor Dame Molly Stevens, PhD, FREng FRS

Oxford University

“Gelomics are developing exciting biomaterials technology that aligns with a sustainable future in biomedical research and development. I look forward to contributing my expertise to advance their ground-breaking work.”

Professor Stevens is the John Black Professor of Bionanoscience at Oxford University, serving in the Institute for Biomedical Engineering and the Department of Physiology, Anatomy & Genetics. She is also Deputy Director of the Kavli Institute for Nanoscience Discovery. Holding a PhD from the University of Nottingham and postdoctoral experience at MIT, she led research at Imperial College London and remains part-time faculty. Additionally, she is a Biomaterials Professor at Karolinska Institutet. Recognized for her work in biosensing, regenerative medicine, and therapeutics, she has published over 400 papers and holds numerous patents, with 4 spin-out companies. Prof. Stevens has received over 40 awards, including the Novo Nordisk Award (2023), and is a Fellow of several prestigious institutions, including the Royal Society.

Distinguished Prof. Dietmar W. Hutmacher, PhD, MBA

Queensland University of Technology (QUT)

“I’m excited to contribute to Gelomics’ pioneering efforts, to support the biomaterials science and tissue engineering and regenerative medicine community with products which allow to strive for reproducibility and enhancement of translational readiness levels of their research endevours.”

Professor Hutmacher, co-founder of Gelomics, and current Director of the Max Planck Queensland Centre for the Materials Science of Extracellular Matrices, is a globally recognised leader in tissue engineering and regenerative medicine. With an illustrious career that blends over decades of industrial and academic excellence, Professor Hutmacher has pioneered numerous biomedical innovations. He has authored over 500 journal articles, edited 14 books, and holds an impressive h-index of 133 with over 75,000 citations. His role at Gelomics will leverage his extensive experience in translating scientific research into impactful commercial and clinical applications, aiming to advance our biomaterials technology to new heights.

Professor Travis Klein, PhD

Queensland University of Technology (QUT)

“I am thrilled to join Gelomics’ Scientific Advisory Board and support the development of innovative, non-animal methodologies that pave the way for more ethical and efficient drug development.”

Professor Klein, also a co-founder of Gelomics, is a distinguished figure in the field of biomedical engineering at the Queensland University of Technology (QUT). As the leader of the Cartilage Regeneration Laboratory, he has been at the forefront of developing regenerative therapies for cartilage defects. His extensive work, which includes senior leadership roles within QUT and has garnered over 10,000 citations, will be invaluable as Gelomics continues to pioneer innovative, non-animal methodologies for drug development.